top of page
お知らせ
vision-logo_edited.png

What we place emphasis on is acting as a stakeholder at sites where medical care is needed.

Our Mission

The purpose of this NPO is to study the various issues that arise between medicine and society from the perspective of governance, and to disseminate the results to society.

In doing so, we place emphasis on actually acting as a stakeholder on the ground. This is because there are things that can only be seen by acting as a person involved.

For example, since the Great East Japan Earthquake, we have continued to provide medical and radiation countermeasure support to the Hamadori region of Fukushima Prefecture, and in doing so, we have maintained a policy of making decisions together with the residents.

By making decisions together with residents in the face of insufficient information, a relationship of trust with residents is built, and the accumulation of such decisions becomes valuable evidence. For past research results, please see "Activities".

Through activities like this, we hope to develop the young people who will lead the next generation. Many young people want to learn a lot while experiencing various things. I'm looking for a "good teacher." However, current school education is not able to provide an educational environment that satisfies these students.

Now that ICT technology has developed, it is possible to achieve unexpected results by connecting like-minded people.

Financial independence is essential for academic independence. However, the current system has many barriers, including cost and operational issues. There is an ironic situation in which relying on the "public" actually makes it less "public." In order to advance medical care and education in a country suffering from financial difficulties, it is necessary to build a system that does not depend on taxes.

　To cultivate new researchers who embody the idea of "public, not public." This is the reason why I started this NPO.
If you are interested in our activities, please feel free to contact us. Welcome.

上昌広（顔写真）.jpg

Masahiro Kami

​

President of the Specific Nonprofit Organization

Medical Governance Research Institute

Graduated from the University of Tokyo Medical School in 1993. Completed graduate studies at the same university in 1999, earning a medical doctorate. Engaged in clinical practice and research in hematologic malignancies at Toranomon Hospital and the National Cancer Center.

 

Since 2005, has been leading the Exploratory Medical Human Network System (later renamed Advanced Medical Social Communication System) at the University of Tokyo Medical Institute, conducting research on medical governance. Retired in March 2016 and assumed the position of President of the Specific Nonprofit Organization Medical Governance Research Institute in April of the same year.

 

Also serves as a visiting professor at Hosei University and Seisa Academic College, and holds positions as board member, advisor, and external director in multiple companies and research institutes.

 

Since the 2011 East Japan Earthquake, has been involved in activities related to recovery, including serving as a committee member for health countermeasures in Soma City, an advisor for radiation countermeasures in Soma City, and a board member of the Specific Nonprofit Organization Soma Follow Arch Team.

 

Areas of expertise include medical governance theory, hematology and oncology, mycology, and medical network theory.

 

Frequently appears on television and radio, and contributes to various media outlets such as magazines, websites, and newspapers, providing medical information and advice on current healthcare issues.

Academic background

3.31.1987

4.1.1987

4.1.1989

3.31.1993

4.1.1995

3.31.1999

Graduated from Nada High School

University of Tokyo Faculty of Liberal Arts Science Class III Admission

Graduate School of Medicine, University of Tokyo

Graduated from the University of Tokyo School of Medicine

Entered Graduate School of Medicine, University of Tokyo

Completed doctoral course at the University of Tokyo Graduate School of Medicine

licence

5.10.1993

National Exam Doctor's License

work history

6.1.1993

6.1.1994

6.1.1995

6.1.1996

​

4.1.1999

4.1.2001

10.1.2005

​

​

11.1.2006

4.1.2007

​

5.1.2011

6.10.2011

2.2012

12.2015

​

12.1.2015

4.1.2016

4.1.2016

​

7.1.2017

5.2018

4.1.2019

6.24.2019

6.1.2020

   4.1.2022

​

​

Resident, Department of Internal Medicine, University of Tokyo Hospital
Resident, Omiya Red Cross Hospital
Department of Hematology, Tokyo Metropolitan Komagome Hospital
Department of Hematology and Oncology, 3rd Department of Internal Medicine, University of Tokyo Hospital
National Public Servants Mutual Aid Association Toranomon Hospital Hematologist
Physician, Department of Pharmacotherapy, National Cancer Center Hospital
Visiting Associate Professor, Department of Exploratory Medicine Human Network Systems, Institute of Medical Science, University of Tokyo(Change of Name)Specially Appointed Professor, Institute of Medical Science, University of Tokyo
Department of Internal Medicine, Gyoda General Hospital (to the present)
Visiting Professor, Teikyo University Medical Information System Research Center (until March 31, 2022)
Soma City Radiation Countermeasures Advisor (to the present)
Soma City Reconstruction Council "Advisory Council Member
A member of the Soma City Special Committee on Health Measures (up to the present)
Visiting Professor, Faculty of Symbiotic Science, Kokusai Gakuen Seisa University (to the present)
Outside Director of SBI Biotech Co., Ltd. (to the present)
Director, Medical Governance Research Institute (to the present)
Doctor of Internal Medicine, Navitas Clinic Shinjuku, Tetsuikai Medical Corporation (to the present)
Wise Co., Ltd. External Director (Until August 31, 2018)
Director, Narita Medical 2038 Research Institute (to the present)
Director of Rectus Co., Ltd. (to the present)
Auditor of Platinum Nursing Co., Ltd. (to the present)
Medical Corporation T.O.P. Doctors Tokyo International Clinic Director (to the present)
Visiting Professor, Rikkyo University (Graduate School of Social Design for the 21st Century) (to the present)

  1. Wang J, Tanimoto T, Zhao T, Tsuda K, Yamashita E, Kami M, Jiang Q. Prevalence of novel coronavirus pneumonia in the early stage of transmission and responding strategies in Japan. Shanghai Journal of Preventive Medicine.(12):E042-E042, 2020

  2. Yoshida I, Tanimoto T, Schiever N, Patelli F, Kami M. Characteristics of Doctors' Fatality due to COVID-19 in Western Europe and Asia-Pacific countries. QJM.113(10):713-714, 2020

  3. Miyachi T, Tanimoto T, Kami M. Evaluation of modelling study shows limits of COVID-19 importing risk simulations in sub-Saharan Africa. Epidemiology & Infection.148:e113, 2020

  4. Ueda M, Yamashita E, Tanimoto T, Kami M. Are less aggressive national lockdowns in COVID-19 associated with enhanced economic activity?. QJM.114(6):359-361, 2021

  5. Ueda M, Tanimoto T, Murayama A, Ozaki A, Kami M. Japan’s Drug Regulation During the COVID‐19 Pandemic: Lessons From a Case Study of Favipiravir. Clin Pharmacol Ther.111(3):545-547, 2021

  6. Kosaka M, Hashimoto T, Ozaki A, Tanimoto T, Kami M. Delayed COVID-19 vaccine roll-out in Japan. THE LANCET. 397(10292):2334-2335, 2021

  7. Yamashita E, Ozaki A, Tsubokura M, Takita M, Tanimoto T, Kami M, Rodriguez-Morales AJ. Safety of SARS-CoV-2 BNT162b2 Vaccine in Elderly Patients from Japan - A Preliminary Assessment and A Call on Careful Pharmacovigilance. Revista Panamericana de Enfermedades Infecciosas.4(1):e8, 2021

  8. Yamamoto K, Mashiba T, Takano K, Suzuki T, Kami M, Takita M, Kusumi E, Mizuno Y, Hamaki T. A Case of Exacerbation of Subclinical Hyperthyroidism after First Administration of BNT162b2 mRNA COVID-19 Vaccine. Vaccines.9(10):1108, 2021

  9. Yashio T, Murayama A, Kami M, Ozaki A, Tanimoto T, Rodriguez-Morales AJ. COVID-19 infection during the Olympic and Paralympic Games Tokyo 2020. Travel Medicine and Infectious Disease.72.8090277777778, 2021

  10. Yamashita E, Takita M, Kami M. Time-Dependent Changes in Death Reports and the Sex Ratio in the Safety Surveillance of SARS-CoV-2 Vaccination in Japan, the United States, and European Countries. Cureus Journal of Medical Science.14(3):e23380, 2022

  11. Sakamoto R, Yoshida M, Bhandari D, Miyatake H, Kosaka M, Tanimoto T, Kami M, Ozaki A. Difficulty in continuing home care after informal caregiver was exposed to the COVID-19: A case report. Clinical Case Reports.10(7):e05804, 2022

  12. Sakamoto R, Bhandari D, Yoshida M, Miyatake H, Kosaka M, Ozaki A, Tanimoto T, Kami M. Implications of end-of-life home care compared with hospital-based care during the COVID-19 pandemic: A case report. Clinical Case Reports.10(7):e05806, 2022

  13. Harada F, Yamamoto K, Matsuda T, Yamamoto C, Tani Y, Ohnishi M, Takita M, Tanimoto T, Kami M, Shineha R. The allergic reaction to anisakis contaminated fish after the first administration of BNT162b2 mRNA vaccine: A case report. Gastroenterol Rep (Oxf).10:goac034, 2022

  14. Saito Y, Yamamoto K, Takita M, Kami M, Tsubokura M, Shibuya K. Effectiveness of the Booster of SARS-CoV-2 Vaccine among Japanese Adolescents: A Cohort Study. Vaccines (Basel).10(11):1914, 2022

  15. Uchi Y, Yamashita E, Kami M, Takita M. Changes in the cause of death in Japan before and during the COVID-19 pandemic. Arch Gerontol Geriatr.111:104993, 2023

  16. Tani Y, Takita M, Kobashi Y, Wakui M, Zhao T, Yamamoto C, Saito H, Kawashima M, Sugiura S, Nishikawa Y, Omata F, Shimazu Y, Kawamura T, Sugiyama A, Nakayama A, Kaneko Y, Kodama T, Kami M, Tsubokura M. Varying Cellular Immune Response against SARS-CoV-2 after the Booster Vaccination: A Cohort Study from Fukushima Vaccination Community Survey, Japan. Vaccines.11(5), 920, 2023

bottom of page